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Synopsis 1 
The Corneal Transplant Follow-up Study II is a prospective trial that has accrued 1077 2 
transplants to determine whether HLA class II matching influences the risk of rejection in 3 
high-risk penetrating keratoplasty.  4 
 5 
Abstract 6 
Purpose: To describe a study to determine the influence of HLA class II matching on 7 
allograft rejection of high-risk, full-thickness corneal transplants.  8 
Methods: A prospective, longitudinal, clinical trial (ISRCTN 25094892) with a primary 9 
outcome measure of time to first clinically determined rejection episode. Tissue typing used 10 
DNA-based techniques. Corneas were allocated to patients with ≤2 HLA class I antigen 11 
mismatches by cohort minimization to achieve 0, 1 or 2 HLA class II (HLA-DR) antigen 12 
mismatches. Transplants were to be followed up at 6 months and then annually on the 13 
anniversary of surgery for 5 years. Power calculations estimated a sample size of 856 14 
transplants to detect a 0.1 difference in probability of rejection at one year between HLA 15 
class II matched and mismatched transplants at the 5% level of significance with 80% 16 
power. 17 
Results: To allow for loss to follow up, 1133 transplants in 980 patients were accrued to the 18 
study between 3 September 1998 and 2 June 2011. 17% of transplants had 0 HLA-DR 19 
mismatches. The most frequent indication was bullous keratopathy, accounting for 27% of 20 
transplants and 54% of the transplants were regrafts. Median waiting time for a matched 21 
graft was 3 months. Donor and recipient characteristics were distributed evenly across the 22 
study groups. 23 
Conclusion: Recruitment to the CFS II has closed with 1077/1133 transplants meeting all the 24 
study criteria. Follow-up has been completed and final analysis of the data has started. 25 
26 
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Despite the avascularity of the cornea in the healthy eye and the historical presumption of 27 
immune privilege in anterior chamber, allograft rejection remains a leading cause of 28 
penetrating keratoplasty (PK) failure.[1-3] Even when rejection episodes are successfully 29 
reversed, there is still a negative impact on long-term graft survival.[4] Penetrating 30 
keratoplasty is being increasingly superseded by endothelial keratoplasty (EK) and deep 31 
anterior lamellar keratoplasty (DALK) but is still required for many patients. In 2015/16, 35% 32 
of corneal transplants recorded in the UK Transplant Registry  were PK (Mark Jones, 33 
personal communication) and a global survey of corneal transplantation based on 2012 data 34 
showed that PK accounted for 70% of transplants.[5] While the risk of rejection appears to 35 
be reduced in DALK and EK, especially for Descemet Membrane endothelial keratoplasty 36 
(DMEK), it is not eliminated.[6 7] Therefore, there remains a need to increase our 37 
understanding of the immunobiology of corneal transplantation in order to improve strategies 38 
for the prevention of rejection, especially for those types of allograft, such as PK, that are 39 
more prone to this serious postoperative complication.  40 
 41 
In organ transplantation there is a clear benefit from human leukocyte antigen (HLA) 42 
matching between donors and recipients.[8] Moreover, the role of donor-specific anti-HLA 43 
antibodies and antibody-mediated rejection in late renal allograft failure is becoming 44 
clearer,[9] which may give insights into the mechanism of late endothelial failure in corneal 45 
transplantation.[10] There have been many reports over the years concerning the influence 46 
of HLA matching on the risk of cell-mediated corneal transplant rejection. These include 47 
retrospective single- and multi-centre registry based studies as well as multi-centre 48 
prospective studies; but there is still no firm consensus on the value of HLA matching.[3 11-49 
18] The Combined Cornea Transplant Study (CCTS) carried out in the USA is one of the few 50 
randomized, prospective studies on HLA matching in corneal transplantation.[15] This 51 
carefully designed study found no effect of HLA matching in high risk patients; however, a 52 
significant error rate in serological tissue typing, especially for HLA class II, was 53 
subsequently discovered.[19] Simulations by Völker-Dieben et al.[11] suggested that errors 54 
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in as few as 5% of tissue types were sufficient to reduce the impact of HLA class II (HLA-55 
DR) matching and that higher numbers of errors completely nullified the benefit of the 56 
intended matching. Errors in HLA typing could therefore explain both the CCTS results 57 
showing no influence of HLA matching and the apparent negative effect of HLA-DR 58 
matching found in a retrospective UK study.[13 15 16 19] While corneal allograft rejection is 59 
typically considered to be cell-mediated, studies in rodents have shown the extent of 60 
redundancy in the immune response and have confirmed that there are several different 61 
immunological pathways that could all lead to rejection.[20] This may provide an alternative 62 
immunological explanation for the lack of consistency in the outcomes of HLA matching 63 
studies in corneal transplantation. Whatever the reasons for these seemingly discordant 64 
outcomes for HLA-DR matching, there appears to be a degree of consensus, with the 65 
exception of the CCTS, for a beneficial effect of HLA class I matching, at least in high risk 66 
grafts.[3 12 14 18 21] However, any potential benefit of matching for a given patient may be 67 
offset by having to wait an unacceptably long time for a suitably matched transplant.[22] 68 
 69 
With reports in the literature suggesting a benefit,[12 14] no benefit,[15] or a negative effect 70 
of HLA-DR matching,[3 13 16] the present study was designed to test the hypothesis that 71 
HLA class II matching, against a background of HLA class I matching, reduces the risk of 72 
allograft rejection in full-thickness corneal transplants. Only transplants considered being at 73 
increased risk of rejection were included in the study. Limiting the study to high risk grafts is 74 
supported by observations in rats that suggested HLA class II matching was beneficial in 75 
regrafts but not first grafts.[23] The risk factors for rejection were based on a previous 76 
study.[3] To avoid the possibility of serological typing errors undermining the accuracy of 77 
HLA matching, all the tissue typing of donors and recipients used DNA-based rather than 78 
serological methodologies.  79 
  80 
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Methods 81 
Study design. A multi-centre, prospective, longitudinal clinical trial registered with ISRCTN 82 
(ISRCTN25094892) and included in the UK National Institute for Health Research Clinical 83 
Research Network portfolio (NIHR CRN Study ID 9871). The study was approved by the 84 
National Health Service South West Multicentre Research Ethics Committee (MREC/97/6/8) 85 
and by the National Research Ethics Service (IRAS Project ID 11351).  All transplants were 86 
matched for HLA class I, defined as not more than two antigen mismatches at the HLA-A 87 
and HLA–B loci combined. The study groups were defined by the number of mismatched 88 
HLA-DR antigens between donors and recipients; namely, 0, 1 or 2 mismatches. 89 
HLA typing. To avoid potential serological tissue typing errors, especially for HLA class 90 
II,[19] DNA-based molecular techniques (PCR-SSO/SSP) were used for low resolution (i.e., 91 
antigen level) typing for all donors and recipients. For class II antigens (HLA-DR), the 92 
matching algorithm included the following splits (the broad antigen is given in brackets): 93 
DR15(2), DR16(2), DR11(5), DR12(5), DR13(6), DR14(6); however, for class I (HLA-A and 94 
HLA-B) donors and recipients were matched only for broad antigen specificities. 95 
Donors. The great majority (87%) of corneas were from organ donors that had already been 96 
tissue typed. The remaining 13% of corneas were from non-organ donors and HLA-typed 97 
using DNA extracted from the neural retina.  98 
Corneal storage. All corneas were stored by organ culture at 34°C in the Bristol and 99 
Manchester eye banks for up to 4 weeks.[24] The minimum endothelial cell density was 100 
2200 cells/mm².[25]  101 
Recipients. Individuals who agreed to participate in the study all gave written informed 102 
consent, which complied with the tenets of the Declaration of Helsinki. The inclusion and 103 
exclusion criteria for patient selection are listed in Table 1.  104 
 105 
 106 
 107 
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Table 1. CTFS II inclusion and exclusion criteria. 108 
Inclusion criteria 109 
Donors HLA typed by PCR-SSP or PCR-SSO 110 
 Corneas stored for up to 4 weeks by organ culture at 34°C 111 
 Endothelial cell density ≥2200 cells/mm² 112 
Recipients Penetrating keratoplasty (PK) 113 
 Patients of either sex aged 16 years or older 114 
 Patients competent to give informed consent  115 
 Patients who have given consent to participate 116 
 HLA type by PCR-SSP or PCR-SSO 117 
 Patients with indications and risk factors that increase the risk of allograft 118 
rejection:[3] regraft, bullous keratopathy, vascularized cornea, active or 119 
past inflammatory/infectious disease (e.g., herpes infection, uveitis), 120 
glaucoma 121 
Exclusion criteria 122 
Donors HLA type by serology 123 
 Corneas not stored by organ culture 124 
 Endothelial cell density <2200 cells/mm² 125 
Recipients Corneal transplant procedures other than PK 126 
 Patients under 16 years old 127 
 Patients not competent to give consent 128 
 Patients who have not given consent  129 
 HLA type by serology 130 
 Patients not at increased risk of allograft rejection 131 
 132 
Patients at increased risk of rejection[3] were registered with NHS Blood and Transplant 133 
(NHSBT) and placed on the UK Transplant Registry waiting list for HLA matched corneal 134 
transplants. The only intervention was the allocation of patients to one of the study groups 135 
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determined by the level of HLA class II mismatching (i.e., 0, 1 or 2 HLA-DR mismatches): the 136 
surgical technique and postoperative management of the patients were according to surgeon 137 
preference.  138 
Sample size. Sample size was estimated using data from a previous retrospective study, 139 
which reported freedom from rejection probability estimates at 1 year for HLA-DR matched 140 
(0 mismatched antigens) and HLA-DR mismatched transplants of, respectively, 0.7 and 141 
0.6.[3] Assuming a ratio of 1:2 matched to mismatched transplants, the sample size required 142 
to detect a difference of 0.1 in probability of rejection at 1 year between the groups at the 5% 143 
level of significance with 80% power was calculated to be 856.  144 
Allocation to study groups. The allocation of corneas to patients was a two-step process. 145 
First, patients were identified who were matched at HLA class I with the cornea donor.  146 
Corneas were then allocated by cohort minimization to these patients to achieve 0, 1 or 2 147 
HLA-DR mismatches with the donor.[26 27] If there were sufficient HLA class I-matched 148 
patients on the waiting list such that a cornea could be assigned to more than one of the 149 
study groups, a weighting factor was used to increase the probability (0.95) that the cornea 150 
would be allocated to the group with the fewest accrued transplants and decrease the 151 
probability of being allocated at random to one of the other groups.  152 
Clinical follow-up data. Data were submitted by surgeons completing NHSBT Ocular Tissue 153 
Transplant Audit forms used for routine data collection for corneal transplants in the UK. 154 
Data were submitted at the time of patient registration with NHSBT, at the time of 155 
transplantation, at 6 months postoperatively and then every 12 months on the anniversary of 156 
the transplant for up to 5 years.  157 
Outcome. The primary outcome measure for the study was time to first clinically determined 158 
allograft rejection episode regardless of whether it led directly to graft failure or was treated 159 
successfully. The criteria for determining allograft rejection included one or more of the 160 
following: red eye, photophobia, loss of vision, cells in the anterior chamber, keratic 161 
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precipitates, endothelial or epithelial rejection line, subepithelial infiltrates, or an area of 162 
localized graft oedema. 163 
Statistical methods. A range of donor, recipient and cornea characteristics are described. 164 
Continuous measures are summarised using mean and standard deviation (SD) or median if 165 
the distribution was skewed, and categorical variables are summarised as number and 166 
percentage. 167 
 168 
Results 169 
Accrual of transplants to the study began on 3 September 1998 and closed on 2 June 2011.  170 
To allow for loss to follow up, a total of 1133 transplants in 980 recipients carried out in 31 171 
hospitals were accrued to the study (see Acknowledgements for list of participating 172 
surgeons). Figure 1 shows the numbers of transplants accrued, excluded and randomized to 173 
the study groups.  174 
Donor characteristics 175 
Mean donor age was 50 (SD 14) years and 54% of donors were male. The mean intervals 176 
between death and enucleation and between enucleation and corneoscleral disc excision 177 
were, respectively, 19.6 (SD 7.1) hours and 17.7 (SD 6.7) hours. Corneas were stored in 178 
organ culture for 20.9 (SD 4.1) days. Mean endothelial cell density was 2684 (SD 231) 179 
cells/mm². Descriptive statistics for the individual study groups are shown in Table 2. 180 
 181 
  182 
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Table 2. Donor variables by study group (0, 1 or 2 HLA-DR mismatches). Mean (SD) given 183 
for continuous variables. 184 
 Number of HLA-DR mismatches 185 
Donor variables 0 1 2 186 
n (%) 182 (17) 482 (44) 413 (39) 187 
Age (y) 51.1 (14.1) 49.9 (13.1) 49.5 (14.2)  188 
Sex (% male) 52 53 56  189 
Death-Enucleation (h) 20.3 (6.9) 19.6 (7.1) 19.3 (7.2)  190 
Enucleation-excision (h) 17.8 (6.7) 17.3 (6.9) 18.2 (6.4)  191 
Storage time (d) 20.8 (4.1) 21.0 (4.1) 21.0 (4.1)  192 
ECD (cells/mm²) 2681 (219) 2676 (225) 2694 (241)  193 
 194 
Recipient characteristics 195 
As expected, recipient age (p<0.0001) but not donor age (p=0.7) varied with indication for 196 
transplantation (Table 3). High risk was defined by both indication and the presence of other 197 
preoperative risk factors. The overall distributions of indications and other risk factors are 198 
shown, respectively, in Table 3 and Figure 2. Of the 1077 transplants that met all the study 199 
criteria and were allocated to the study groups, 136 had none of the other risk factors (i.e., 200 
the indication by itself was considered to increase the risk of rejection), 293 transplants had 201 
1 of the other risk factors and 646 transplants had >1.  202 
 203 
  204 
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Table 3. Distribution of indications and mean (SD) recipient and donor ages.  205 
Indication n (%) Recipient age (y) Donor age (y) 206 
Ectasias 75 (7) 41.6 (13.9) 50.1 (13.6) 207 
Dystrophies 235 (21) 67.3 (13.3) 50.7 (12.2) 208 
Previous ocular surgery 310 (27) 69.8 (13.9) 50.2 (14.0) 209 
Infection 200 (18) 58.5 (17.3) 48.3 (14.7) 210 
Injury 75 (7) 48.9 (16.3) 49.8 (14.1) 211 
Ulcerative keratitis 21 (2) 57.1 (17.6) 49.6 (13.4) 212 
Opacification 61 (5) 58.7 (18.4) 51.7 (12.9) 213 
Miscellaneous 156 (14) 58.7 (16.9) 49.9 (14.7) 214 
Total 1133 61.7 (17.3) 50.0 (13.7) 215 
  p<0.0001 p=0.7 216 
 217 
The distribution of HLA-DR mismatches is shown in Table 2. There was a preponderance of 218 
transplants with 1 or 2 HLA-DR mismatches and 182 transplants (17%) had 0 HLA-DR 219 
mismatches. Sixty-two percent of patients waited 3 months or less for an HLA matched 220 
transplant: 78% waited ≤6 months and 87% received a matched transplant within 12 months 221 
of being registered for the study (Figure 3).  222 
 223 
Discussion 224 
Allograft rejection remains a serious postoperative complication following corneal 225 
transplantation, especially for PK. Even with the increasing preference for EK, which has 226 
reportedly lower rates of rejection than for PK,[6 7] it is still important to better understand 227 
corneal transplant rejection and to explore ways to reduce the risk especially since globally 228 
just 30% of corneal transplants are lamellar procedures.[5]  229 
 230 
 12 
 
The varying results from studies on HLA matching in corneal transplantation could be due to 231 
several factors, including study design (typically retrospective), low numbers of transplants 232 
(i.e., low statistical power), HLA serological typing errors, and different HLA matching 233 
strategies (e.g., class I only, class II only, both class I and II, or overall number of matched 234 
HLA antigens ignoring whether class I or class II). In view of these equivocal results, the  235 
CTFS II was designed to investigate the influence of HLA class II matching, against a 236 
background of HLA class I matching, in a large, well-defined cohort of high risk PKs in a 237 
prospective clinical trial. Class II matching was targeted because of the results from different 238 
studies suggesting a benefit of matching,[11 28] no influence of matching[29] or a 239 
detrimental effect of matching.[3 13]  240 
 241 
So far as the inclusion criteria are concerned, some consider pseudophakic bullous 242 
keratoplasty (PBK) to be a moderate- rather than a high-risk graft; however, in a previous 243 
study we found that the relative risk of rejection at one year for PBK was similar to that for 244 
regrafts and therefore believe the inclusion of PBK in the CTFS II to be justified.[3] 245 
Moreover, it is likely that the level of risk will vary between the different factors included in 246 
the selection criteria for defining grafts at risk of rejection. Regression coefficients for each of 247 
the risk factors in the final Cox proportional hazards model will help quantify the level of risk 248 
for each factor and, potentially, allow a prognostic index to be generated to determine the 249 
overall level of risk for different combinations of factors. 250 
 251 
The most widely accepted way to avoid bias in prospective clinical trials is to use random 252 
allocation of patients to treatment groups. With sufficient numbers, there should be no 253 
systematic differences between the study groups in patient characteristics and other 254 
variables, other than the allocated treatment, likely to influence the trial outcome. For the 255 
CTFS II, a classic randomized trial would have involved allocating each patient to receive a 256 
specific level of HLA class II match (i.e., 0, 1 or 2 HLA-DR mismatches) at the time of 257 
recruitment to the study, with each patient having an equal chance of being allocated to one 258 
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of the three study groups. Finding a specific level of HLA mismatch for a cornea depends on 259 
the donor HLA type and the distribution of HLA types of recipients on the waiting list – the 260 
larger the waiting list, the more likely it is to achieve the required level of matching for the 261 
cornea. However, the level of matching that can be achieved for a given patient depends 262 
purely on their own HLA type and the HLA type of the donor cornea available at any one 263 
time. The genes of the human major histocompatibility complex (HLA) are highly 264 
polymorphic, resulting in hundreds of different alleles at each HLA locus. Therefore, random 265 
allocation could result in a patient being allocated to a study group where the likelihood of 266 
achieving the required level of matching would be wholly unrealistic within a reasonable 267 
time. This would be unethical and could result in highly unbalanced study groups. 268 
 269 
In order to optimize the balance between the CTFS II study groups, we chose to use the 270 
method of minimization, which, according to Altman and Bland,[26 27] is a valid alternative 271 
to full randomization. Minimization includes a random element, which, for CTFS II, meant 272 
that a cornea would be allocated with a defined probability to a patient with whichever level 273 
of HLA class II mismatch would minimize the overall imbalance between numbers of 274 
transplants in the respective study groups. Despite this, there was a preponderance of HLA-275 
DR mismatched transplants; however, the study groups were balanced in their respective 276 
distributions of donor factors (Table 2) and indication for transplantation (data not shown). 277 
While a degree of age matching between donors and recipients is practised in the UK to 278 
avoid corneas from very old donors being allocated for very young recipients, this was not 279 
the case for CTFS II where the primary allocation criterion was HLA match, ignoring donor 280 
age. Since the great majority of HLA-typed eye donors (87%) were also organ donors, the 281 
mean donor age of 50 (SD 14) years was lower than the overall mean of 61 (SD 18) years 282 
for UK eye donors and extreme donor-recipient age differences were not therefore a 283 
concern.  284 
 285 
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The CTFS II was designed to test the hypothesis that HLA class II matching reduces the risk 286 
of rejection in high-risk penetrating keratoplasty. Analysis of the data to establish whether 287 
this hypothesis is correct has started now that all the transplants have completed their follow 288 
up.  289 
 290 
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Figure legends 
Figure 1. Numbers of transplants accrued, excluded and randomized to the study groups. 
Figure 2. Distribution of preoperative risk factors (n=1701) in the 1077 transplants allocated 
to the study groups and percentages of transplants with each risk factor. 
Figure 3. Distribution of patient waiting times for HLA matched transplants. 
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Figure 2. Distribution of preoperative risk factors (n=1701) in the 1077 transplants allocated 
to the study groups and percentages of transplants with each risk factor. 
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Figure 3. Distribution of patient waiting times for HLA matched transplants. 
 
